Manuscripts
Showing 1556 manuscripts.
Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.
Citation
Carmen D. Zorrilla, Russell B. Van Dyke, Arlene D. Bardeguez, Edward P. Acosta, Elizabeth (Betsy) Smith, Michael Hughes, Sharon Huang, Heather D. Watts, Barbara E. Heckman, Barbara E. Heckman, Eleanor Jimenez, George D. McSherry, Lynne M. Mofenson. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.. Antimicrobial Agents and Chemotherapy. 2007. 51: 2208 - 2210. PMID: 17420209Year
2007
Journal
Antimicrobial Agents and Chemotherapy
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels. Results of a prospective randomized trial (AIDS clinical trial group 5125s)
Citation
Pablo Tebas, Jiameng Zhang, Kevin E. Yarasheski, Scott Evans, Margaret A. Fischl, Abby Helen Shevitz, Judith Feinberg, Ann C. Collier, Cecilia M. Shikuma, Barbara Brizz, Fred Richard Sattler. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels. Results of a prospective randomized trial (AIDS clinical trial group 5125s). Journal of Acquired Immune Deficiency Syndromes. 2007. 45: 193-200.Year
2007
Journal
Journal of Acquired Immune Deficiency Syndromes
Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis
Citation
Nancy Radcliffe Reynolds, Junfeng Sun, Haikady N. Nagaraja, Allen L. Gifford, Albert W. Wu, Margaret A. Chesney. Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis. Journal of Acquired Immune Deficiency Syndromes. 2007. 46: 402-9.Year
2007
Journal
Journal of Acquired Immune Deficiency Syndromes
Phase 2 study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211
Citation
Daniel R. Kuritzkes, Roy (Trip) Gulick, Zhaohui Su, Charles Flexner, Michael Hughes, Paul Skolnik, Timothy J. Wilkin, Robert Gross, Amy Krambrink, Eoin Coakley, Wayne Greaves, Andrew R. Zolopa, Richard C. Reichman, Catherine Godfrey, Martin S. Hirsch. Phase 2 study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. Journal of Infectious Diseases. 2007. 196: 304-12.Year
2007
Journal
Journal of Infectious Diseases
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial
Citation
Bruce R. Schackman, Callie A. Scott, Paul Edward Sax, Elena Losina, Timothy J. Wilkin, John Ernest McKinnon, Susan Swindells, Milton C. Weinstein, Kenneth A. Freedberg. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clinical Infectious Diseases. 2007. 45: 1062-70.Year
2007
Journal
Clinical Infectious Diseases
Lipids and lactate in human immunodeficiency virus-1-infected pregnancies with or without protease inhibitor-based therapy
Citation
Elizabeth Livingston, Susan Ellen Cohn, Yang Yang, Heather D. Watts, Arlene D. Bardeguez, Theodore Benjamin Jones, Laura M. Smith, Triin Umbleja, Grace McComsey. Lipids and lactate in human immunodeficiency virus-1-infected pregnancies with or without protease inhibitor-based therapy. Obstetrics and Gynecology. 2007. 110: 391-7.Year
2007
Journal
Obstetrics and Gynecology
Data monitoring in clinical trials using prediction
Citation
Scott Evans, Li-Fang Li, Lee-Jen Wei. Data monitoring in clinical trials using prediction. Drug Information Journal. 2007. 41Year
2007
Journal
Drug Information Journal
HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells
Citation
Nicole L. Yonkers, Benigno Rodriguez, Anthony B. Post, Robert Asaad, Linda Jones, Michael M. Lederman, Paul V. Lehmann, Donald D. Anthony. HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells. Journal of Infectious Diseases. 2007. 194: 391-400.Year
2007
Journal
Journal of Infectious Diseases
TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function
Citation
Wei Jiang, Michael M. Lederman, Clifford V. Harding, Benigno Rodriguez, Richard Mohner, Scott F. Sieg. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. European Journal of Immunology. 2007. 37: 2205-13.Year
2007
Journal
European Journal of Immunology
Challenges in using observational studies to evaluate adverse effects of treatment
Citation
Michael Hughes, Paige L. Williams. Challenges in using observational studies to evaluate adverse effects of treatment. New England Journal of Medicine. 2007. 356: 1705-7.Year
2007
Journal
New England Journal of Medicine